<DOC>
	<DOCNO>NCT00854802</DOCNO>
	<brief_summary>The purpose study compare several Debio 025 ( alisporivir ) /peg-IFNα2a/ribavirin triple therapy current standard care ( SOC ) treatment naïve chronic hepatitis C genotype 1 patient .</brief_summary>
	<brief_title>A Study Debio 025 ( Alisporivir ) Combined With Peg-IFNα2a Ribavirin Treatment naïve Chronic Hepatitis C Genotype 1 Patients</brief_title>
	<detailed_description>This international , multicentre , randomise , double-blind , placebo-controlled , 4-arm , parallel-group , multiple dose phase II study compare 3 Debio 025 ( alisporivir ) /peg-IFNα2a/ribavirin regimen SOC treatment treatment naïve chronic HCV genotype 1 patient . Patients randomise 1 4 arm receive either Debio 025/peg-IFNα2a/ribavirin triple therapy fix treatment duration 48 week ( Treatment A ) 24 week ( Treatment B ) , Debio 025/peg-IFNα2a/ribavirin triple therapy response-based treatment duration 24 48 week ( Treatment C ) , blind SOC treatment 48 week ( Treatment D ) . Follow-up 24 week treatment arm .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Males female age ≥ 18 ≤ 65 year . Body mass index ( BMI ) ≥ 18 ≤ 32 kg/m^2 . Hepatitis B surface antigen ( HbsAg ) negative HIV1 negative . Serological diagnosis chronic hepatitis C viral infection genotype 1 &gt; 6 month . Chronic liver disease consistent chronic hepatitis C infection biopsy FibroScan® obtain within past 24 month ( 36 month patient incomplete/transition cirrhosis ) . Previously untreated hepatitis C virus ( HCV ) infection ( approved investigational drug ) . Plasma HCV RNA level lower limit ≥ 100 IU/ml assess quantitative polymerase chain reaction ( qPCR ) equivalent ; upper limit . Neutrophil count ≥ 1500/µL ; hemoglobin ( Hb ) ≥ 12g/dL female ≥ 13g/dL male ; platelet ≥ 90,000/µL . Patients incomplete/transition cirrhosis biopsy elasticity score 9.5 14 kPa FibroScan must abdominal ultrasound ( US ) , compute tomographic ( CT ) scan , magnetic resonance imaging ( MRI ) scan without evidence hepatocellular carcinoma ( within 2 month prior randomisation ) serum alphafoetoprotein ( AFP ) &lt; 100 ng/mL . Aspartate aminotransferase ( ASAT ) alanine aminotransferase ( ALAT ) &lt; 5 time upper limit normal . Normal compensate liver function absence complicate portal hypertension document follow : No history bleed oesophageal varix ; Absence ascites ; Absence encephalopathy ; Albumin ≥ 35 g/L ; Total bilirubin ≤ 1.8 mg/dL ( ≤ 30 µmol/L ) ; Prothrombin ( INR ≤ 1.5 ) . Creatinine clearance &gt; 50 mL/min . Thyroid stimulate hormone ( TSH ) within normal range ; All patient inform Debio 025 ribavirin foetotoxicity : Females may participate surgically sterile postmenopausal . Premenopausal females may participate use 2 reliable contraceptive method ( oral contraceptive + barrier method ) . The contraceptive regimen must maintain treatment period 4 month last Debio 025 ribavirin dose . Male patient must surgically sterile use 2 reliable contraceptive method ( oral contraceptive + barrier method ) . The contraceptive regimen must maintain treatment period 7 month last Debio 025 ribavirin dose . Signed informed consent study procedure . Negative pregnancy test within one week first investigational product administration female patient child bear potential . Treatment investigational drug within 6 month prior first dose investigational product . HCV genotype different genotype 1 . Any previous HCV treatment ( approved investigational ) . Histologic evidence complete hepatic cirrhosis ( include compensate cirrhosis ) base previous liver biopsy ( available ) . Ongoing recent use medication ( include counter medication herbal product ) within 2 week study start within 5 drug halflives medication ( whichever longer ) know inhibitors/inducers cytochrome P450 ( CYP450 ) 3A , substrates Pglycoprotein 1 ( PgP ) , substrates/inhibitors organic aniontransporting polypeptide ( OATP ) , multidrug resistanceassociated protein 2 ( MRP2 ) , bile salt export pump ( BSEP ) mention list unauthorised medication ; Any medical contraindication pegIFNα2a and/or ribavirin treatment ; Any cause relevant liver disease HCV include limited hepatitis B virus ( HBV ) , drug alcoholrelated cirrhosis , autoimmune hepatitis , haemochromatosis , Wilson 's disease , nonalcoholic steatohepatitis ( NASH ) , primary sclerosing cholangitis ( PSC ) , primary biliary cirrhosis ( PBC ) . Any condition , opinion Investigator , would make patient unsuitable enrollment could interfere patient participate complete study . Patients risk factor ( hypertension diabetes ) need ophthalmologic investigation ( include fundoscopy ) . History moderate , severe , uncontrolled psychiatric disease , especially depression , include history hospitalisation prior suicidal attempt . Uncontrolled arterial hypertension , ie , patient systolic BP ≥ 160 mmHg and/or diastolic BP ≥ 100 mmHg . History pancreatitis , uncontrolled diabetes mellitus , retinopathy . Antinuclear antibody ( ANA ) titre &gt; 1:640 screen and/or evidence autoimmune hepatitis liver biopsy . Alcohol consumption &gt; 20 g/day female &gt; 30 g/day male . History major organ transplantation exist functional graft . Pregnancy lactation . Haemoglobinopathies ( thalassaemia major , sickle cell anaemia drepanocytosis ) . Familial history severe neonatal cholestasis pregnancy cholestasis . Evidence active suspect cancer , history malignancy risk recurrence ≥ 20 % within 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>